(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -19.04% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.33%.
Macrogenics's revenue in 2026 is $167,673,000.On average, 9 Wall Street analysts forecast MGNX's revenue for 2026 to be $7,148,434,985, with the lowest MGNX revenue forecast at $3,683,144,812, and the highest MGNX revenue forecast at $9,917,482,114. On average, 8 Wall Street analysts forecast MGNX's revenue for 2027 to be $6,484,679,037, with the lowest MGNX revenue forecast at $3,745,570,996, and the highest MGNX revenue forecast at $10,422,624,597.
In 2028, MGNX is forecast to generate $5,633,262,337 in revenue, with the lowest revenue forecast at $3,745,570,996 and the highest revenue forecast at $8,507,796,976.